Furthermore, our data suggest that specific oncogenic mutations may influence the effectiveness of ICIs against AML after allo-HCT, with TIM-3 blockade potentially benefiting patients with specific mutations and high TIM-3 ligand expression. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.